Table 3.

Non-clinical package proposed for pre-IND/SA.

	Study conducted	Information collected
Pharmacology studies	Model selection	Validate the most appropriate model to evaluate the impact of chronic treatment in future in vivo studies
	Strain selection	Identify a C. minuta candidate strain for further development as an LBP to target obesity
	In vivo efficacy	Address the efficacy of the drug candidate
	Dose ranging	Identify a putative dose-dependent efficacy of Xla1
Safety studies	Translocation	Demonstrate that Xla1 does not present any risk of treatment-induced bacterial infection
	High-dose tolerance and wash out	Evaluate the impact of an acute exposure to the highest concentration technically achievable